Sue Stucker, NP
Family · Central Square, NYNPI 1346584034
Payments from drug & device makers
Across 337 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- GSK$902
- AstraZeneca$520
- Lilly USA, LLC$451
- Pfizer$416
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$392
- plus $2K from 26 others
What the payments were for
- Consulting fees$1503%
- Food & beverage$5,71796%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 72 | $1,119 |
| GSK | 45 | $902 |
| AstraZeneca | 32 | $520 |
| Lilly USA, LLC | 25 | $451 |
| Pfizer | 22 | $416 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 36 | $392 |
| Exact Sciences | 19 | $388 |
| AbbVie | 24 | $379 |
| Astellas Pharma US Inc | 8 | $244 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $168 |
| Baxter Healthcare | 1 | $150 |
| Phathom Pharmaceuticals, Inc. | 5 | $143 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $91 |
| Axsome Therapeutics, Inc. | 4 | $82 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $80 |
| Abbott | 5 | $78 |
| Bayer | 2 | $40 |
| Intuitive Surgical | 1 | $35 |
| Nestle Healthcare Nutrition Inc. | 2 | $29 |
| Arbor Pharmaceuticals, Inc. | 2 | $28 |
| Kowa Pharmaceuticals America, Inc. | 1 | $24 |
| Verona Pharma, Inc. | 1 | $23 |
| Biogen | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Tolmar, Inc. | 1 | $20 |
| Corcept Therapeutics | 1 | $20 |
| Merck | 1 | $19 |
| Bardy Diagnostics, Inc. | 1 | $17 |
| Phadia US Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Genentech USA, Inc. | 2 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,967 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 145 | $184,359 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $37,191 |
| Invega SustennaPaliperidone Palmitate | 11 | $34,721 |
| EliquisApixaban | 46 | $31,227 |
| MounjaroTirzepatide | 16 | $25,156 |
| FarxigaDapagliflozin Propanediol | 21 | $23,614 |
| MyrbetriqMirabegron | 23 | $20,258 |
| JanuviaSitagliptin Phosphate | 12 | $20,137 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $18,170 |
| TrulicityDulaglutide | 12 | $14,353 |
| TradjentaLinagliptin | 20 | $10,034 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,888 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 134 | $4,583 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $4,549 |
| Varenicline Tartrate | 13 | $3,865 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,119 | $184,359145 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $902 | $42,07959 claims |
| Lilly USA, LLCMounjaro, Trulicity | $451 | $39,50928 claims |
| PfizerEliquis | $416 | $31,22746 claims |
| AstraZenecaFarxiga, Symbicort | $520 | $26,91935 claims |
| Astellas Pharma US IncMyrbetriq | $244 | $20,25823 claims |
| MerckJanuvia | $19 | $20,13712 claims |
| Boehringer IngelheimTradjenta | $16 | $10,03420 claims |
| AbbVieSynthroid | $379 | $1,69125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.
Other family in Central Square
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
- Fara StrickerGlen Oaks$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.